Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

# Efficacy and Feasibility of SMS M-Health for the Detection of Adverse Events Following Immunisation (AEFIs) In re-Source-Limited Setting–The Zimbabwe Stimulated Telephone As-Sisted Rapid Safety Surveillance (Zm-STARSS) Randomised Con-Trol Trial

Priscilla PM Nyambayo<sup>1\*</sup>, Michael S Gold<sup>2</sup>, Ushma C. Mehta<sup>3</sup>, Stephen Clarke<sup>4</sup>, Rumbidzai Manyevere<sup>1</sup>, Libert Chirinda<sup>1</sup>, Edlyne N Zifamba<sup>1</sup> and Tatenda Nyamandi<sup>1</sup>

<sup>1</sup>Pharmacovigilance and Clinical Trials Division, Medicines Control Authority of Zimbabwe, Harare, Zimbabwe.

<sup>2</sup>University of Adelaide, Discipline of Paediatrics, Women's and Children's Health Network, Adelaide, Australia.

<sup>3</sup>Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, South Africa.

<sup>4</sup>Flexis Systems Pty Ltd, Australia

\*Correspondence: pnyambayo@mcaz.co.zw .

Abstract: Introduction: The mHealth active participant centred (MAPC) adverse events following immunisation (AEFI) surveillance is a promising area for early AEFI detection resulting in risk minimisation. Passive (spontaneous) AEFI surveillance is the backbone for vaccine pharmacovigilance, but has inherent drawbacks of under reporting, and requires strengthening with active surveillance methods. The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomized controlled trial (RCT) sought to evaluate the efficacy and feasibility of AEFI detection using a short message service (SMS) and computer assisted telephone interview (CATI) approach. Method: A multicentre Zm-STARSS RCT enrolled consented adult vaccinees or parents or guardians of children receiving vaccines, including COVID-19 vaccines, at study vaccination clinics. At enrolment study participants were randomised to either SMS-CATI group or control group. SMS prompts were sent on days 0-2 and 14 post-vaccination to SMS-CATI group to ascertain if a medical event following immunisation (MEFI) had occurred. However, no SMSs were sent to the control group. SMS-CATI group who responded "Yes" to SMS prompts were interviewed by research healthcare workers (RHCWs) who completed a CATI to determine if an MEFI/AEFI had occurred whilst an AEFI in control group was determined from passive AEFI reporting channels. The primary study outcome was the AEFI detection rate in the SMS-CATI group compared to the control group. Results: A total of 704 (31%) participants responded to the SMS prompts, with 75% (528/704) indicating "No" and 25% (176/704) "Yes" to experiencing a MEFI. However, 31% (55/176) who responded "Yes" did not complete a CATI survey, but 69% (121/176) did; and 64% (77/121) of these indicated negative to AEFI experience whilst 36% (44/121) were affirmative. There were no AEFI reported in control group participants. Zm-STARSS showed promising results in that the AEFI detection rate using SMS-CATI was 2% (44/2280) on an intention to treat cohort. Conclusion: Despite the low SMS response and CATI completion rate, we demonstrated that Zm-STARSS SMS system improves AEFI detection compared to passive AEFI surveillance. We recommend cost-effective multi-channel digital approaches for holistic pharmacovigilance to improve AEFI detection in LMICs for all vaccines.

**Keywords:** Zimbabwe Stimulated Telephone Assisted Rapid Safety Surveillance (Zm-STARSS) **m**Health **a**ctive **p**articipant-**c**entred (MAPC) Adverse Events Following Immunisation(AEFI) surveillance

# Table 1: Glossary of key terms

STARSS	Stimulated Telephone Assisted Rapid Safety Surveillance
Zm-STARSS	Zimbabwe Stimulated Telephone Assisted Rapid Safety Surveillance
Au-STARSS	Australian Stimulated Telephone Assisted Rapid Safety Surveillance
ADR	adverse drug reaction
AEFI	Adverse Events Following Immunization
API	Application Programming Interface
AVSS	Active vaccine safety surveillance
CATI	Computer Assisted Telephone Interview
Econet	Econet Wireless Zimbabwe Ltd
eHealth	Electronic health
HCW/HCWs	Healthcare worker(s) or research healthcare workers
HICs	High-Income Countries
МАРС	mHealth active participant-centred
MCAZ	Medicines Control Authority of Zimbabwe
MedDRA	Medical Dictionary for Regulatory Activities
MEFI	Medical Events Following Immunisation
m-Health	Mobile health
POTRAZ	Postal and Telecommunications Regulatory Authority of Zimbabwe
PT(s)	Preferred term(s)
RHCW(s)	Research Health Care Workers(s)
SOC(s)	System organ classification(s)
WBR	Web-Based Reporting
ZEPI	Zimbabwe Expanded Programme on Immunization

# 1. Introduction

A functional national immunisation programme is integral to enhance public health and pandemic preparedness. A key priority for each immunisation programme should be vaccine pharmacovigilance and in particular the surveillance of adverse events following immunisation (AEFI). Passive post-marketing AEFI surveillance is recommended globally. However, there are both inherent limitations and significant challenges in implementing this method. First, the e-Health technology, which mobile health (m-Health) is part of, is now applied globally to improve health surveillance and outcomes. A noteworthy area is the application of digital tools to improve immunisation programmes including AEFI surveillance. Secondly, the m-Health for active vaccine safety surveillance (AVSS) is eliciting growing interest because of its ability to engage consumers directly to elicit AEFI reports, which could overcome some of the limitations inherent in passive reporting by health professionals(3-5). The m-Health active participant-centred (MAPC) AEFI surveillance could be defined as a data collection system that seeks to ascertain as completely as possible the number of AEFIs in a defined population via a continuous organised process(1).

The m-Health approaches are showing promise as a tool to improve AEFI detection in many high-income countries (HICs). This approach directly prompts vaccinees or their caregivers to report an AEFI quickly and seek care (3-6). A Canadian scoping review of MAPC AEFI surveillance suggests that mHealth could be the method for collecting selfreported subjective symptoms from vaccinees which could complement existing AEFI surveillance systems (5). The study recommends the evaluation of digital solutions to improve vaccine surveillance systems for contemporary and future public health needs (5). The performance of these m-Health approaches in LMIC settings is poorly described with only Cambodia (7) and Sierra Leone (8) reporting on their experiences for active m-Health adverse drug reaction (ADRs) but not on AEFIs. Moreover, the underperformance of the m-Health system in aboriginal communities in Australia highlights the need to assess the feasibility and performance of such systems in culturally diverse populations with poor socioeconomic groups (9).

A comprehensive evaluation of SMS-based AEFI surveillance is required prior to diverting scarce public health resources towards widespread implementation (4). The Australian <u>s</u>timulated <u>t</u>elephone <u>a</u>ssisted <u>r</u>apid <u>s</u>afety <u>s</u>urveillance (Au-STARSS) is one of two published randomised controlled trials (RCT) which has compared the AEFI detection rate in an active (SMS surveillance) and control (passive surveillance) groups. The study evaluated the feasibility and acceptability of SMS based surveillance using a two-step process with an initial SMS being the entry point for detection whilst a subsequent digital interaction elicited information to determine the nature of the event (4). The outcome of the Au-STARSS study showed a 13-fold greater AEFI detection rate in the SMS group (Pearson'  $\chi^2$ test =76.0, p<0.0001) compared to the control group (passive surveillance) (4).

Established in 1997, the Zimbabwe national AEFI surveillance system has continued to grow, but the burden of reporting AEFIs by overwhelmed health workers (HCWs) has remained a key barrier to the timely detection of serious or severe AEFIs (10, 11, 12). Zm-STARSS RCT is a proof-of-concept study evaluating SMS based surveillance for AEFI detection in a LMIC using an adapted Au-STARSS mHealth platform. The objective was to ascertain if STARSS could be adapted, implemented, and evaluated in Zimbabwe for the detection of AEFI.

#### 2. Aim and hypothesis.

The primary aim was to determine if Zm-STARSS was more effective in detecting an AEFI than routine passive reporting of AEFIs. The primary hypothesis was that the proportion of people in which an AEFI is detected is greater in the SMS intervention group compared to a comparison group (passive surveillance). The secondary aim was to provide a narrative description covering the challenges of establishing a Zm-STARSS platform.

#### 3. Methods and Materials

#### 3.1. Study population, sample size and inclusion criteria

A total of 4560 individuals presenting for vaccination at CITIMED and Chitungwiza hospitals in peri-urban Chitungwiza near Harare, Zimbabwe, were eligible for enrolment from November 2020 to August 2021. Participants were eligible if they understood English (Zimbabwe's official language), were adult vaccinees, or were parents or guardians of vaccinated children under the age of 18 years, had access to a functional mobile phone and consented to being part of the study. **Exclusion criteria:** Vaccinees who were unwell before vaccination, child vaccinees associated with multiple births (e.g., a twin child) and children with a parent/guardian ≤18 years were not eligible for enrolment.

## 3.2. Consent process

Opt-in, informed consent was sought. Participants were informed that the study was examining diverse ways of monitoring vaccine 'side-effects' and that they could receive a follow-up SMS to ascertain any medical event requiring attention, together with an invitation to provide further details (by CATI) of their 'experience' during the post-vaccination period. Consent was obtained for receipt of SMSs, participation in a CATI interview and access to any passive AEFI reports submitted to Zimbabwe Expanded Programme on Immunisation (ZEPI) and Medicines Control Authority of Zimbabwe (MCAZ) through a database search for performance of a causality assessment by the national AEFI Committee.

## 3.3. Study design and randomisation

The Zm-STARSS software was customised to include all national ZEPI antigens including COVID-19 vaccines. Zm-STARSS study design included only two randomised groups (SMS and control) and excluded the web-based component which was in the Au-STARSS, because of the high cost and limited internet access to health care workers (HCWs) and vaccinees. The Zm-STARSS trial was a multi-centre, single-blinded and active-controlled parallel two-grouped RCT with a repeated measures design to collect responses to SMS's sent on days 0-2 and 14 post-immunisations to ascertain whether the participant had experienced a medical event following immunisation (MEFI). Participants were enrolled at both CITIMED and Chitungwiza hospitals vaccination sites. Site selection was based on availability of reliable internet services to enable the platform to func-Randomisation was implemented using an algorithm residing in the study server tion. which allowed automatic allocation in a 1:1 ratio in permuted sequence to the SMS intervention or the control group. The participant was the unit of allocation, which occurred on receipt of the vaccinee's immunisation and demographic data into the study portal. Research healthcare workers (RHCWs) involved with the enrolment of participants and immunisation providers were blinded to allocation.

#### 3.4. SMS dispatch and response

Extraction of participant and vaccinee data from a completed enrolment form was entered manually by RHCWs, via a secure web portal, and within 48 hours of vaccination. Upon receipt of this data an information technology (IT) application, located on the MCAZ server, automated SMSs to be dispatched without daily restriction (with a curfew between 8 PM and 8AM) and managed the flow of outgoing and incoming SMSs which included customised SMS replies to these responses. On receipt of the enrolment data participants were reminded via SMS that they should expect follow-up messages on days 0-2 and 14 post-immunisations. These time intervals were consistent with the expected temporal onset of reactions for the vaccines administered to the participants in the study. Each prompt SMS message aimed to determine if a MEFI had occurred by asking the question: "Since vaccination has the person who has been vaccinated seen a medical doctor, nurse, pharmacist, healthcare worker or health traditional healer because the child or adult vaccinated has been unwell?' Please respond "Yes" or "No." Those who responded "Yes" were contacted telephonically to complete an AEFI report which took the form of a CATI administered by a RHCW. The purpose of the CATI was to obtain details about the MEFI so that it could be determined if this was consistent with the WHO, AEFI definition(12). The CATI interview questionnaire included most of the 25 AEFI core variables as recommended by WHO(12). The "No" SMS responders were sent an automated SMS acknowledgement. A final SMS prompt was sent on day14 post-vaccination. The specific wording of the SMSs is detailed in **Table 2**.

Table2: Details of the wording of the SMS's generated following enrolment and randomisation to the SMS-CATI intervention group.

Vaccination day Reminder SMS Day 0-2 (within 48 hours)	Welcome to the STARSS Study. 'Since vaccination has the person who has been vaccinated experienced an MEFI or seen a medical doctor, nurse, pharmacist healthcare worker or health traditional healer because the child or adult vaccinated has been unwell?' Please respond Yes or No'.
Reminder SMSs Day 14	Welcome to the STARSS Study. 'Since vaccination has the person who has been vaccinated experienced an MEFI or seen a medical doctor, nurse, pharmacist healthcare worker or health traditional healer because the child or adult vaccinated has been unwell?' Please respond Yes or No'.
SMS response from portal to "YES" participants	Randomised to SMS mHealth Computer Assisted Telephone Interview (CATI)
reply at days 0- 2 and 14	STARSS Study: "Thank you for letting us know that you received health advice after the vaccination. We will call you in the next 24 hours to find out more".

The CATI sought to verify the following details on day 0-2 and 14 post vaccination if participants responded Yes to the SMS prompts: 1) vaccine(s) administered and batch numbers already prefilled at enrolment on the online Zm-STARSS by the nurses and also available on participant's hard copy vaccination card; 2) type of medical attention sought; 3) adverse symptom(s); 4) other details including hospitalisation and recovery. An AEFI report was regarded as confirmed if the reported vaccination details were the same as those documented through the Zm-STARSS online recruitment portal, if medical attention/attendance following the immunisation was confirmed and one or more symptom(s) were reported. No follow-up occurred for the participants randomised to the control and the occurrence of an AEFI was determined from the ZEPI and MCAZ AEFI database/AEFI line listing.

### 3.5. Zm-STARSS-information technology (IT) platform

The Zm-STARSS IT platform was centralised, with encrypted data transmitted securely from the two study sites to a secure MCAZ server. The IT platform provided a single site for the collation of participant demographics, immunisation data, and SMS messages including repository for all data collected from CATI reports. The platform automatically dispatched and received SMS messages. The vaccinee's immunisation details (vaccine antigen(s), brand, batch number, vaccine administration site(s), date, and time together with demographic information (vaccinee's name, date of birth (DOB), sex, address, and mobile number) were collected at enrolment. Participant reports of a MEFI automatically triggered an email alert to RHCWs. Access to the site was password protected and RHCWs had access to the global dashboard. All portals offered a real-time view of the MEFI and AEFI reports, and all data was added to a single structured query language (SQL) database stored in the study server, which allowed export of the data (CSV format) and circumvented the need for unsecure data transmission. The Zm-STARSS surveillance system was developed with assistance from Econet Wireless Zimbabwe Ltd (Econet), (a company with 65% mobile phone market share) and in line with the Postal and Telecommunications Regulatory Authority of Zimbabwe(POTRAZ) requirements for SMS mobile phone test codes. A major challenge was that participants would have insufficient telephone credit, to respond to the automatic SMS messages. This could introduce a significant bias in the perceived responsiveness of participants, and the reported/unreported symptoms. To address this issue, Econet created a test channel pre-paid by MCAZ, where participants' SMSs were not charged, and hence successful transmission could be achieved despite insufficient telephone credit.

#### 3.6. AEFI outcome measures and definitions

For the SMS-CATI group a MEFI notifier was defined as a participant who replied "Yes" to the SMS prompt on at least one of the time points (0-2 or 14 days). A participant was deemed to not have had a MEFI if a "No" response was received at any of the time points. A MEFI was defined as completed when all four CATI verification steps had occurred. An event was classified as an AEFI if it met the WHO case definition. Zimbabwe's national AEFI expert committee trained by WHO performed the causality assessment on all reported cases according to WHO AEFI causality assessment algorithm (2019)(13). Some participants however might experience more than one AEFI, e.g., abscess and convulsions.

The number of AEFI cases in each group (SMS vs control) formed the basis for the analysis of the primary outcome. Since multiple MEFI/AEFI reports may have been completed for the same participant, the primary outcome was based on a single individual. For the control group all AEFI reports for the duration of the RCT, were matched to the vaccinee's details (name, date of birth (DOB), etc.) to determine if a report had been received within 21 days of vaccination. Any submitted report was counted as an AEFI for the control group.

#### 3.7. Secondary outcomes

SMS compliance was assessed by the number and percentage of participants who responded with a "Yes" or "No" response to the surveillance SMS. Fully compliant responders were defined as responders at the three points (0-2 and 14 days), partial compliers were those responding at 0-2 or 14-days' time points and non-compliers never responded at all. MEFI completion was assessed by the number and percentage of participants, in the SMS-CATI group, who notified an MEFI and whose report was completed and verified by the RHCWs. The time for detection of an AEFI was defined as the time (in hours) from medical attendance/attention to completion of the MEFI report for the SMS-CATI group or the time from healthcare attendance to receipt of an AEFI report by ZEPI or MCAZ for the control group.

#### 3.8. Statistical analysis plan

The primary analyses were performed on the intention-to-treat (ITT) population, with participants analysed per their allocated pools. Given the low AEFI cases expected in the control group, two-tailed Fisher's exact tests ( $\alpha$ =0.025) were done to compare the events in the SMS group to those in the control group. Pearson'  $\chi^2$  tests were carried out for the different demographic characteristics, such as gender, age, sex, index of socio-economic advantage and disadvantage as well as the vaccine characteristics to determine any significant differences in the SMS group and control groups, including those partici-

pants who responded "Yes" or "No" to the SMS or the non-responders to any SMS. Median and 95% confidence intervals based on the binomial distribution were used to describe the median time in hours of the various time lags from enrolment to AEFI detection.

# 4. Results

# 4.1. Eligibility, enrolment, randomisation, and intention to treat numbers.

Between November 2020 and August 2021, a total of 5,541 eligible adults and children attending the two immunisation sites were approached and screened for enrolment. A total of 4,560 who met inclusion criteria and signed the consent forms were enrolled and randomly assigned (1:1) equally to the SMS or the control groups, and 981 subjects were excluded with details documented in the consort diagram (**Figure 1**).



# Figure 1: Zm-STARSS CONSORT diagramme for Intention To Treat analysis.

**\*\* n=**55 Participants who responded "Yes" to SMS day 0-2 and/or 14 prompts post vaccination were however considered lost to follow since they did not respond to the RHCWs phone calls (3 attempts at different times) to conduct a CATI survey to ascertain if the "Yes" meant if the person vaccinated had experienced a MEFI/AEFI or not.

# 4.2. Participant demographic and vaccine characteristics.

The demographic and vaccine characteristics of enrolled participants are detailed in **Table 3**. Whilst participants were distributed across a wide age range (birth to 65 and above years), 2,551 (55.9%) were aged from birth to 6 months (or with almost equal gender balance (females 2,157 or 47.3% and males 2,401 or 52.7%). A total of 11 different vaccines were administered to 4,560 participants, with the following combinations being administered; Bacille Calmette-Guerin BCG (37.5%) was the most frequently administered followed by Sinopharm COVID-19 vero cell vaccine (27.7%), Sinovac COVID-19 vero cell vaccine (18.2%), oral polio vaccine (OPV) - Pneumococcal-Pentavalent (DTP-Hib-HepB)-Rotavirus (6.9%), Diphtheria Tetanus Pertussis (DTP) booster Measles Rubella (MR) (5.0%), Pneumococcal Rotavirus (4.3%) PCV and Sputnik V COVID-19 vaccine (0.1%). **Table 3** shows that the Pearson  $\chi^2$  tests have no significant differences in any of the demographic or vaccine characteristics between the SMS intervention or control groups except for the education status p=0.042 that is statistically significant, with marginally more individuals in the SMS-CATI group having a degree or A level (Cambridge/ZIMSEC).

**Table 3.** Gender, age, socio-economic status, and vaccine characteristics of participants in each trial arm.

	SMS-CATI	Control	Total	Pearson	Comment
	group	group		Chi-	
	n=2280 (%)	n=2280 (%)	n=4560 (%)	Square 95% CI p value	
Site Chitungwiza Central CITIMED	1160 (50.9) 1120(49.1)	1161(50.9) 1119(49.1)	2321(50.9) 2239(49.1)	p=0.976	NS
Gender - Female	1053 (46.2)	1104 (48.4)	2157 (47.3)	p=0.318	NS
- Male	1226 (53.8)	1175 (51.6)	2401 (52.7)		
- Other	1 (0.0)	1 (0.0)	2		
			(0.0)		
Age range					NS
Median (IQR)					
0 - 6 months	1280 (56.1)	1273 (55.8)	2551 (55.9)	p=0.884	
7 months - 5 years	212 (9.3)	212 (9.3)	424 (9.4)		
6 - 14 years	1 (0.0)	0 (0.0)	1		
15 - 39 years	301 (13.2)	297 (13.0)	(0.0)		
40 - 64 years	374 (16.4)	393 (17.2)	580 (12.7)		
65 years and above	112 (4.9)	105 (4.6)	758 (16.6)		
			246 (5.4)		
Marital status					
D - divorced	6 (0.3)	6 (0.3)	12 (0.3)	p=0.877	NS
F - de Facto	1 (0.0)	3 (0.1)	4 (0.1)		
M - married	2,009 (88.1)	2,001 (87.7)	4,010 (87.9)		

9	of	19
---	----	----

S - single	201 (8.8)	202 (8.9)	403 (8.8)		
W - widowed	63 (2.8)	68 (3.0)	131 (2.9)		
Widowed	05 (2.0)	00 (5.0)	151 (2.7)		
Education					
D - degree	255 (11.2)	199 (8.7)	454 (10.1)	p=0.042	SIG
I - diploma	201 (8.8)	218 (9.6)	419 (9.1)	1	
C - Certificate	7 (0.3)	8 (0.4)	15 (0.3)		
A - Cambridge/ZIMSEC	224 (9.8)	202 (8.8)	426 (9.3)		
A' level	1,593 (69.9)	1,653(72.5)	3,246(71.2)		
Work Status					
Unemployed	715 (31.4)	715(31.4)	1,430(31.3)	p=0.917	NS
Employed by organiza-	708 (31.1)	704(30.9)	1,412(31.0)		
tion	566 (24.8)	572(25.1)	1,138(25.0)		
Domestic duties	221 (9.7)	229(10.0)	450(10.0)		
Self employed	70 (3.1)	60 (2.6)	130 (2.7)		
Student					
Housing Status					
Owned	1,334(58.5)	1,347(59.1)	2,681(58.8)	p=0.696	NS
Rented	946(41.5)	933(40.9)	1,879(41.2)		
Number of vaccines re-					
ceived.	1,649 (72.3)	1,643 (72.1)	3,292 (72.2)	p>0.05	NS
1	118 (5.2)	110 (4.8)	228 (5.0)		
2	98 (4.3)	97 (4.3)	195 (4.3)		
3	415 (18.2)	430 (18.8)	845 (18.5)		
4					
Vaccines administered.					
RCC	864 (37.0)	848 (37.2)	1712 (37.5)	n>0.05	NS
DTP booster ODV DCV	1 (0 0)	1 (0 0)	2	p>0.03	GNI
Potovirus	1 (0.0)	1 (0.0) 07 (4.3)	(0,0)		
DTP booster MP OPV	98 (4.3)	$\frac{97}{1}$ (4.3)	(0.0)		
DTP hooster-MR_OPV	118 (5 2)	110 (4.9)	1		
Pentavalent	151 (6.6)	164 (7.2)	(0,0)		
MR		3 (01)	228 (5.0)		
Sinopharm COVID-19	633 (27.8)	628 (27 5)	315 (6.9)		
Sinovac COVID-19	414 (18 2)	428 (18 8)	4		
	11 (10.2)	120 (10.0)	(0.1)		
			1261 (27.7)		
			842 (18.2)		
			842 (18.2)		

NS - Not Significant SIG-Significant

Table 4: Adverse symptoms in the individuals randomised to the SMS-CATI intervention group.

AEFI	Reaction	AEFI reaction	CATI	Suspected	Causality
(MedDRA	) System	MedDRA	group	Vaccine(s)	assessment**
Organ	Classification	Preferred Terms	(n=2280)		
(SOC)		(PT)			
		Abscess	2 (0.09)	BCG(1)	A1

10 of 19

General disorders and			OPV-PCV-Pentavalent-	
administration site			Rotavirus(1)	
conditions	Injection site	5 (0.2)	BCG(2)	A1
	pain/ injected		OPV-PCV-Pentavalent-	
	limb pain		Rotavirus(3)	
	Crying	2 (0.09)	OPV-PCV-Pentavalent-	A1
			Rotavirus(2)	
Skin and subcutaneous	Boils	2 (0.09)	Sinovac COVID-19 vaccine(2)	B1
tissue disorders				
	Rash	10 (0.4)	BCG(4)	A1(9), C(1)
			MR(1)	
			OPV-PCV-Pentavalent-	
			Rotavirus(4)	
			Sinovac COVID-19 vaccine(1)	
Respiratory, thoracic	Chest pain	2 (0.09)	Sinovac COVID-19 vaccine(1)	B1
and mediastinal	1		Sinopharm COVID-19 vaccine(1)	
disorders	Cough	3 (0.1)	Sinovac COVID-19 vaccine)1)	B1(1)
		- ()	OPV-PCV-Pentavalent-	C(2)
			Rotavirus(2)	0(-)
	Difficulty	3 (0 1)	OPV-PCV-Pentavalent-	<u> </u>
	breathing	0 (0.1)	Rotavirus(3)	C
Gastrointestinal	Diarrhea	8 (0 4)	BCG(1)	A1
disorders	Diamica	0 (0.1)	MR(2)	7 <b>11</b>
disorders			OPV-PCV-Pentavalent-	
			Rotavirus(3)	
			Sinovas COVID 19 vassing(1)	
			Sinopharm COVID-19 vaccine(1)	
	Loss of apportito	3 (0 1)		A1(1) B1(2)
	Loss of appende	5 (0.1)	Sincura COVID 10 yearing(2)	A1(1), D1(2)
	Vanitina	Q (0 4)		A 1/() D1/0)
	vomiting	8 (0.4)	BCG(3)	A1(6), D1(2)
			MIK(1)	
			DTP booster-MR-OPV(1)	
			OPV-PCV-Pentavalent-	
			Rotavirus(2)	
			Sinopharm COVID-19 vaccine(1)	
Nervous system	Fatigue	2 (0.09)	Sinovac COVID-19 vaccine(2)	A1
disorders				
	Headache	3 (0.1)	Sinovac COVID-19 vaccine(3)	A1
Infections and	Fever	21 (0.9)	BCG(5)	A1
infestations		(***)	DTP booster-MR-OPV(1)	
			MR(2)	
			·····( <i>L</i> )	

		OPV-PCV-Pentavalent-	
		Rotavirus(12)	
		Sinovac COVID-19 vaccine(1)	
Other	16 (0.7)		A1(3),B1(5),
symptoms++			C(7), U(1)

<sup>++</sup>These AEFI reactions include chills, cramps, bloated stomach, jaundice, nasal congestion, nausea, oral thrush, pimples on head, redness, seizures, swelling and tonsils. There was one unfortunate case where a 1-day old baby girl died after BCG vaccination. She experienced fever on the same day post vaccination, she deteriorated and was subsequently hospitalized. She was treated with antibiotics and intravenous fluids, but she didn't improve. Post-mortem was not conducted hence the cause of death could not be determined.

\*\*Causality assessment classification based on WHO AEFI Algorithm 2019 key is as follows: **A1.** Vaccine productrelated reaction, **B1.** Temporal relationship is consistent but there is insufficient definitive evidence for vaccine causing event (may be new vaccine-linked event), **C.** Coincidental-Underlying or emerging conditions or conditions caused by exposure to something other than vaccine, and **U.** Unclassifiable fatal case due to lack of post-mortem.

# 4.3. Primary outcome determination of MEFI notification, verification, report completion and AEFI causality classification.

The SMS responses, MEFI completion and final AEFI classification for the participants randomised to the SMS-CATI group are detailed in **Figure 2**. A total of 6,840 SMSs were dispatched to the participants within 0-2 and 14-days post-vaccination. Overall, 69% (1,576/2,280) of participants, in the SMS intervention groups, were classified as non-compliant. Of the 704 SMS (31% of 2280) responses received, 75% (528/704) indicated that "No" MEFI had been experienced whilst 25% (176/704) responded "Yes" to experiencing an MEFI,( **Figure 2**) at one or more of the time points (day 0-2 and/or 14). In this group of 176 participants, 81 were partial compliers (responded to one SMS) and 95 were complete compliers (responded to all SMS). Of the 176 who were "Yes" respondents 31% (55/176) could not be contacted for a CATI despite at least 3 separate attempts. The remaining 69% (121/176) were contacted successfully by RHCWs who completed their CATI and 36% (44/121) of these were assessed as they met the WHO AEFI criteria. The remainder 64% (77/121) did not experience any AEFI. No passive AEFI reports were identified in the control group after verification of the ZEPI and MCAZ AEFI databases.

The overall health care attended AEFI in the SMS intervention group was 2% (44/2,248) with no AEFI detection in the control group. The AEFI detection rate was 2% greater in the SMS group compared to the control group (0%) which was significantly higher Pearson's  $\chi^2 = 44.19$  for AEFI detection at p<0.0001. Pearson's  $\chi^2_1 = 44.19$ , *p*<0.0001; Fisher's exact test (2-sided), *p*<0.0001) which is statistically significant. The non-response rates to SMS prompts did not differ significantly for the day 0-2 and 14 post vaccination SMS prompts. However, those participants who responded to the SMS ("Yes" or "No") compared with the non-responders demonstrated Pearson X<sup>2</sup> significant differences for education level, employment, and housing status but not for marital status, gender, and number of children, as shown in **Table 5**.



# Figure 2: SMS-CATI group participants – SMS response, MEFI report notification, verification of AEFI report completion.

**Table 5.** Participants randomised to SMS-CATI who responded ("Yes" or "No") compared with non-responders to day 0-2 and 14 SMS according to demographic and socioeconomic status.

Participants who	Pearson Chi	Comment		
responded	square P Value			
(Yes or No) vs non-				
responders				
Education Level	< 0.001	O Level and below disproportionately were non-responders		
Employment Status	< 0.001	The unemployed and those employed by organizations		
		disproportionately were non-responders		
Housing Status	0.005	Homeowners disproportionately were non-responders		
Marital Status	0.217	Marital status did not affect response rates		
Gender	0.16	Gender did not affect response rates		
Number of Children	0.115	Number of children did not affect response rates		

# 4.4. Reported AEFIs and causality assessment classifications in the SMS group.

The adverse symptom and causality assessment classifications of those in the SMS group are shown in **Table 6** including the Medical Dictionary for Regulatory Activities (MedDRA) term reactions system organ classifications (SOCs) and preferred terms (PTs), suspected vaccines, and causality assessment outcomes done by the National AEFI Committee using the WHO AEFI causality assessment algorithm (2019)(13). Fever was reported with an overall rate of 0.9% and all other symptoms occurred with a frequency of less than 0.5%. In the ITT analysis 2% (44/2,248) of all SMS participants experienced an AEFI and reported seeking health advice from HCWs. Of these, 25% (11/44) were hospitalised including one fatality (Table 6). The reported rate of hospitalisation was 0.5% (11/2,280). Participants sought advice mostly from a community health advisor (57%) followed by a pharmacist (18%), GP (13.6%) or nurse (11.4%).

# Table 6: Type of medical attendance or attention in those participants with a reported MEFI/AEFI forZm-STARSS,RCT mHealth CATI intervention group.

0 1				
Medical attendance type	n	%		
General Practitioner	6	13.6		
Pharmacy	8	18.2		
Nurse	5	11.4		
Other*	25	56.8		
Total	44	100.0		

\*Other: This includes use of herbal remedies, treatment with household remedy analgesics anti-pyretics by consulting relatives,

4.5. *Time to detection of an AEFI.* 

For those SMS participants who had a confirmed MEFI the time to detection of an AEFI was determined (**Table 7**). For the time periods of vaccination to symptom onset and vaccination to MEFI notification there was a wide distribution as expected because participants received vaccines with a variable reactogenicity profile. However, the median time was 17.0 hours (CI 95%: 9.0-23.0) from onset of symptoms to presenting for medical attention, regardless of when this occurred following immunisation. The median time from medical attendance to Zm-STARSS completion of an AEFI report was 525.6 hours (CI 95%: 487.6-581.2).

Table 7: Time to AEFI detection; Surveillance time points (in hours) in participants with confirmed AEFIs for Zm-STARSS, RCT mHealth SMS CATI intervention group.

Time points	SMS mHealth	Calculation
	CATI	
	Group in hours	
	(95% CI)	
Vaccination to onset of symptoms	17.0	Onset symptoms (React Time) -Vaccination
	(9.0-23.0)	Time (Enrolment Time)
Onset of symptoms to medical	93.1	Medical Attention (Medic time) - Onset
attendance/attention	(68.5-115.9)	symptoms (React Time)
Medical attendance/attention to	525.6	MEFI/AEFI report (Create Time)-
completed MEFI report	(487.6-581.2)	MEFI/AEFI notification (Medic Time)
		=Time to AEFI detection that is primary
		study end point.

# 5. Discussion

The STARSS platform was designed to address some of the deficiencies inherent in passive surveillance with low rates of AEFI detection. If an AEFI occurred and not be reported, this was due to barriers in the AEFI reporting cycle, confusion among HCWs of what type of events constitute a reportable AEFI and unsatisfactory reporting processes (15-17). Targeting consumers is a strategy to improve AEFI reporting (3-5, 16). Our SMS surveillance prompts were designed to ascertain if a serious or severe event, which prompted health care attention or attendance, had occurred. We designed the first SMS questionnaire to include a broad range of health care and community health care advisors with the aim of capturing as many potential AEFI as possible. Using the Zm-STARSS we demonstrated that the detection rate of health care attention and/or attended AEFI using SMS-based surveillance exceeded reporting by passive surveillance. This occurred despite high non-compliance rates to SMS responses. Contrasting the Au-STARSS with the Zm-STARSS provides some valuable insights into the implementation of SMS based surveillance in a LMIC. The SMS-based AEFI detection rates in Zm-STARSS were 2%, which compares with a rate of 5.3% in the Au-STARSS-CATI group. For AEFI passive surveillance the rates were 0% and 0.3% (respectively, for Zm and Au-STARSS). Overall, hospitalisation rates, following immunisation, were 6-fold higher for Zm-STARSS (0.5%) compared with Au-STARSS rate (0.08%), which is likely to reflect co-incidental diseases, including SARS Cov-2 infection. This underlies the importance of performing causality assessment for serious AEFI reports, using the WHO methodology(13) to differentiate adverse vaccine reactions from co-incidental events, which occurred in Zm-STARSS but not in the Au-STARSS. Collectively these trials have demonstrated the utility of the STARSS platform in both HIC and LMIC settings.

The SMS non-compliance rate in Zm-STARSS was 69% compared with 9.7 % in the Au-STARSS, although the latter had an additional time point for a solicited response (Day 7). SMS non-compliance (response) rates have varied between different SMS AEFI surveillance studies and a comparison has limitations because of the variability in the timing, number of and content of the SMSs, different populations, cultures, mHealth services cost in LMICs, and study settings(4). In general, studies with opt-in consent show non-compliance rates which vary between 10-30% (4, 19, 20). There are several likely reasons for non-compliance rates in Zm-STARSS. First, it was noted that a low education level and unemployment was associated with a higher rate of non-response both factors which need further interrogation. Second, the study was conducted during the peak of the COVID-19 pandemic with inherent challenges in implementation of the study with some HCWs and community members succumbing to COVID-19 and some of the RHCWs testing COVID-19 positive required quarantine and prolonged absence from work from time to time. Furthermore, access to phone credit in a LMIC setting is likely to be a significant barrier to SMS responses. We conclude that SMS in LMICs could be ineffective where mobile phone plan pricing structures often encourage data-only plans (without an allocated phone number) and where phones are often used with Wi-Fi communications only. Future studies should investigate the use of online/digital messaging services such as WhatsApp, Viber, Meta messenger and Sasai. The preferred platforms would obviously depend on local popularity, and support for multiple pathways may be required for best coverage. The IT platform could connect to the API gateways of these services and send instant messages through their networks instead of the telephone network. These options are likely to introduce their own issues around privacy and confidentiality in capturing and recording recipient health information and around adverse treatment of messages by spam filters. However, digital services do not rely on a formal mobile number, they rather offer the promise of broader access to the local population than SMS and avoid the issue around transmission of replies being prevented due to lack of credit on the participant phone. In LMICs, SMS platforms on cheaper mobile phones are more accessible than online/digital messaging. If a user is offline, there is no communication. Furthermore, the user requires smartphone/tablet/computer to go online/digital, which is more expensive than a flip phone. We may therefore conclude that using online/digital messaging, in addition to SMS could be more effective in LMICs if resources permitted.

In the Zm-STARSS, 69% of the "Yes" respondents completed a CATI survey compared with 83% in the Au-STARSS-CATI group. As noted above this is likely a reflection of the context of the Zm-STARSS during the COVID-19 pandemic and the limitations of availability of telephone credit and connectivity in a LMIC. Of the 64% (77/121) SMS "Yes" respondents who did not actually experience an AEFI it might be due to cultural reasons as most Shona speaking people who were most of the study participants usually regard "Yes" as to imply they are alright or in good health. Similarly, due to cultural factors, Shona people do not always RSVP to wedding/birthday invitations, funerals etc. and hence the high non-response rates to the post-vaccination SMS prompts.

The median time of about 17.0 hours (CI 95%:9.0-23.0) from onset of symptoms to presenting for medical attention, regardless of when this occurred following immunisation, were similar for Zm-STARSS and Au-STARSS. However, the median time from medical attendance to completion of an AEFI report in Zm-STARSS [525.6 hours (CI 95%:(487.6-581.2)] was longer than the Au-STARSS [74.8 hours (CI 95%:(54.3-96.1)], for the CATI arm. This is likely to reflect the difficulties for RHCWs in implementing the Zm-STARSS trial particularly during the COVID-19 pandemic. MAPC web-based reporting (WBR) has the potential advantage of a shortened time to AEFI detection as demonstrated in the Au-STARSS. However, this is currently difficult in a LMIC because of limited internet connectivity and expensive online/digital tools. Further studies are required to using

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 30 March 2023

appropriately and timely communication methods to ascertain the barriers to obtaining information about health care attended events following immunisation for vaccinees or their guardians.

The Zm-STARSS has demonstrated the utility of an SMS-based surveillance platform to enhance AEFI reporting as shown in Au-STARSS(4). This has been demonstrated despite higher non-compliance and non-CATI completion rates in a LMIC setting. The researchers were so far not aware of any publications evaluating MAPC AEFI surveillance in Africa. The relative costs and benefits of implementing active SMS-based AEFI surveillance in addition to passive surveillance remains to be determined and should be considered using evidence-based cost-effective holistic approaches of integration with other existing or future m-Health, e-Health including digital initiatives in resource limited settings.

#### 6. Conclusion

SMS-based AEFI surveillance can improve AEFI detection in an LMIC setting and should be considered as an approach to augment passive surveillance in these settings for both COVID-19 vaccines and childhood vaccines although the challenges of using SMS mentioned in the discussion ought to be addressed. The findings of Zm-STARSS should inform the wider use of SMS-based AEFI surveillance which is particularly relevant at this time since establishing robust and novel pharmacovigilance systems to monitor existing and novel pandemic vaccines. The utility of SMS-based surveillance in AEFI signal detection is another useful risk minimisation factor amongst other considerations for evidencebased integration with other e-Health, digital health, and m-Health systems in resourcelimited settings.

#### 7. Limitations, confounding factors and/or bias.

The limitations of the inherent resource and technology limited challenges of Zm-STARSS resulted in a different study design of only 3 SMS prompts with no WBR component unlike Au- STARSS. The use of a Zm-STARSS test code meant that some participants could not be enrolled if they only subscribed only to the other two mobile phone operators. We are uncertain if the participants who had responded "Yes" to day 0-2 and 14 SMS prompts but did not respond to CATI surveys by the RHCWs could have sought medical attention. Confounding factors and bias were minimised by the RCT study design. Additionally, further studies are required to investigate the reasons for the high SMS non-response rates and to identify other factors that may predict response rates in LMIC settings. The study sites included the largest vaccination clinics in a peri-urban setting in Chitungwiza hence the results might not be representative of a rural population.

**Ethics approval and consent to participate:** The Zm-STARSS (II) RCT (ACTRN12614001046695) was approved by the Medical Research Council of Zimbabwe (MRCZ) ethical approval referenced MRCZ/A/2268 and MRCZ ethical exemption (reference E/148) from consenting participants for passive AEFI surveillance. Ethical approvals were also obtained from the Director of Health Services City of Chitungwiza Municipality Department and the University of Cape Town (UCT) Human Research Ethics Committee (HREC 184/2020) for the Zm-STARSS study. The data was published in deidentified anonymised format.

**Consent for publication:** The authors obtained consent for publication of the manuscript from the MCAZ National Pharmacovigilance Centre the custodian of the safety data since this is a work-related study.

Competing of interest: The authors declare no conflict of interest nor potential competing interest.

**Funding:** The MCAZ funded the study in line with its mandate of the Zimbabwe National Pharmacovigilance Centre. However, additional funding was obtained from unrestricted research grants from the WHO, and Au-STARSS Project, University of Adelaide, Australia. **Author Contributions:** Author Contributions. PPMN designed the study and wrote the main manuscript as the lead author. PPMN, LC, RM, TN, and ENZ conducted the study. MSG and SC provided Zm-STARSS Technical IT support, and copy rights based on AU-STARSS Australia, University of Adelaide innovation. MSG, SC, and UM supervised the study, data cleaning and reviewed the manuscript. PPMN analysed data and performed major analysis including tables and figures. All authors read and approved the final manuscript.

**Acknowledgments:** The authors acknowledge the two study sites management and staff Chitungwiza Central Hospital and CITIMED Private Hospital vaccination clinics, Zimbabwe Expanded Program on Immunisation (ZEPI-MoHCC), MCAZ management and NPC staff, HCWs, and all participants who participated in the Zm-STARSS study, and the national AEFI Committee experts who did the AEFI causality assessment.

## References

 Heininger U, Holm K, Caplanusi I, Bailey S, Abdoellah SA, Arellano F, et al. Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety–executive summary. Vaccine. 2017;35(32):3917-21.

2. Ross J, Stevenson F, Lau R, Murray E. Factors that influence the implementation of e-health: a systematic review of systematic reviews (an update). Implementation science. 2016;11(1):1-12.

3. Cashman P, Macartney K, Khandaker G, King C, Gold M, Durrheim DN. Participant-centred active surveillance of adverse events following immunisation: a narrative review. Int Health. 2017;9(3):164-76.

4. Gold M, Lincoln G, Cashman P, Braunack-Mayer A, Stocks N. Efficacy of m-Health for the detection of adverse events following immunization–The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial. Vaccine. 2021;39(2):332-42.

5. Psihogios A, Bota AB, Mithani SS, Greyson D, Zhu DT, Fung SG, et al. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study. Vaccine 2022;40;4065-4080.

6. Cashman P, Moberley S, Chee K, Stephenson J, Chaverot S, Martinelli J, et al. Participant centred safety surveillance of health care workers receiving influenza vaccination. Vaccine. 2019;37(18):2427-9.

7. Baron S, Goutard F, Nguon K, Tarantola A. Use of a text message-based pharmacovigilance tool in Cambodia: pilot study. Journal of medical Internet research. 2013;15(4):e68.

8. Tsafack M, Ateudjieu J. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone" beep" in a Cameroon health district: a randomized field trial. Pan African Medical Journal. 2015;22(1).

9. Cashman P, Munnoch S-A, Clark K, Allan N, Clarke S, Macartney K, et al. The Aboriginal gap in online active vaccine safety surveillance. Australian Indigenous HealthBulletin. 2020;1(1):3.

10. Masuka JT, Khoza S. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017. BMC Public Health. 2019;19(1):1166-.

11. Shaum A, Mujuru HA, Takamiya M, Ticklay I, Nathoo K, Sreenivasan N, et al. Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe. Vaccine 2022;40(26); 3573-3580.

 Nyambayo PP, Manyevere R, Chirinda L, Zifamba EN, Marekera SF. Descriptive Research Study of the Adverse Events Following Immunization (AEFIs) Surveillance System in Zimbabwe. Clinical Case Reports and Studies. 2023 Volume 2, Issue 1 https://www.doi.org/brs/2023/ccrs/0023

13. <u>https://www.who.int/publications/i/item/9789241516990</u> (accessed 24/3/23)

14. Bohn-Goldbaum E, Cross T, Leeb A, Peters I, Booy R, Edwards KM. Adverse events following influenza immunization: understanding the role of age and sex interactions. Expert Review of Vaccines. 2022;21(3):415-22.

15. Gidudu JF, Shaum A, Dodoo A, Bosomprah S, Bonsu G, Amponsa-Achiano K, et al. Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana. Vaccine. 2020;38(5):1009-14.

16. Clothier HJ, Selvaraj G, Easton ML, Lewis G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunother. 2014;10(12):3726-30.

17. Dey A, Wang H, Quinn H, Hiam R, Wood N, Beard F, et al. Surveillance of adverse events following immunisation in Australia annual report, 2017. Commun Dis Intell. 2019;43:1-28.

18. Jacoby P, Glover C, Damon C, Fathima P, Pillsbury A, Durrheim D, et al. Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study. BMJ open. 2020;10(2):e031851.

19. Munnoch S-A, Cashman P, Peel R, Attia J, Hure A, Durrheim DN. Participant-Centered online active surveillance for adverse events following vaccination in a large clinical trial: feasibility and usability study. Journal of Medical Internet Research. 2019;21(10):e14791.

20. Stuurman AL, Verstraeten T, De Schryver A. Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study. Expert review of vaccines. 2017;16(2):187-91.